| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Tuesday’s Close |
|---|---|---|---|---|---|
| MNTA | Momenta Pharmaceuticals, Inc. | $27.4 | $2.15B | N/A |
Analysts Estimate Momenta Pharmaceuticals (MNTA) to Report a Decline in Earnings: What to Look Out for
http://www.zacks.com/stock/news/773609/analysts-estimate-momenta-pharmaceuticals-mnta-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-773609
Feb 19, 2020 - Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Can The Uptrend Continue for Momenta Pharmaceuticals?
http://www.zacks.com/stock/news/730488/can-the-uptrend-continue-for-momenta-pharmaceuticals?cid=CS-ZC-FT-tale_of_the_tape|20_day_moving_average-730488
Jan 23, 2020 - As of late, it has definitely been a great time to be an investor Momenta Pharmaceuticals
0
Novartis (NVS) Gets Approval for MS Drug Mayzent in Europe
http://www.zacks.com/stock/news/728495/novartis-nvs-gets-approval-for-ms-drug-mayzent-in-europe?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-728495
Jan 21, 2020 - Novartis' (NVS) MS drug, Mayzent, obtains approval in Europe for the treatment of adult patients with secondary progressive multiple sclerosis.
0
Momenta Pharmaceuticals Inc (MNTA) Q3 2019 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2019/10/31/momenta-pharmaceuticals-inc-mnta-q3-2019-earnings.aspx?source=iedfolrf0000001
Oct 31, 2019 - MNTA earnings call for the period ending September 30, 2019.
0
Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q3 2019 Results - Earnings Call Transcript
https://seekingalpha.com/article/4301058-momenta-pharmaceuticals-inc-mnta-ceo-craig-wheeler-q3-2019-results-earnings-call-transcript?source=feed_sector_healthcare
Oct 31, 2019 - Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Q3 2019 Earnings Conference Call October 31, 2019, 08:30 AM ET Company Participants Patty Eisenhaur - VP of IR and Corporate Communications Craig Wheeler -
0
Momenta Pharmaceuticals (MNTA) Reports Q3 Loss, Tops Revenue Estimates
http://www.zacks.com/stock/news/595198/momenta-pharmaceuticals-mnta-reports-q3-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-595198
Oct 31, 2019 - Momenta (MNTA) delivered earnings and revenue surprises of -14.29% and 39.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
0
Momenta Pharmaceuticals (MNTA) Expected to Beat Earnings Estimates: Should You Buy?
http://www.zacks.com/stock/news/582161/momenta-pharmaceuticals-mnta-expected-to-beat-earnings-estimates-should-you-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-582161
Oct 24, 2019 - Momenta (MNTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q1 2019 Results - Earnings Call Transcript
https://seekingalpha.com/article/4260113-momenta-pharmaceuticals-inc-mnta-ceo-craig-wheeler-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare
May 05, 2019 - Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Q1 2019 Earnings Conference Call May 02, 2019, 08:30 ET Company Participants Patricia Eisenhaur - VP, IR & Communications Craig Wheeler - President, CEO
0
Momenta Pharmaceuticals Inc (MNTA) Q1 2019 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2019/05/02/momenta-pharmaceuticals-inc-mnta-q1-2019-earnings.aspx?source=iedfolrf0000001
May 02, 2019 - MNTA earnings call for the period ending March 31, 2019.
0
Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
http://www.zacks.com/stock/news/403482/momenta-pharmaceuticals-mnta-may-report-negative-earnings-know-the-trend-ahead-of-next-weeks-release?cid=CS-ZC-FT-403482
Apr 25, 2019 - Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Page 1>